rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Enanta Pharmaceuticals, Inc.

ENTA · Nasdaq

Health CareBiotechnologyNot moving yet

ENTA stood above a rising 150-day average in 33 of the last 52 weekly readings, and has been out of that trend for the last 6 weeks. It is 13.5% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 6
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$183K
Officials’ trades on record
3
Institutions holding
117 (-10)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 33 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$167K$0$240KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

3 disclosed lines: House 3, Senate 0, executive 0; 2 people.

WhoDidAmountTraded
Daniel S. Goldman House: U.S. House ClerkNY10sold$1k–$15k12 Jul 2023filed 13 Aug 2023
Thomas MacArthur House: U.S. House ClerkNJ03sold$1k–$15k27 May 2015filed 7 Jun 2015
Thomas MacArthur House: U.S. House ClerkNJ03bought$1k–$15k20 Mar 2015filed 11 Apr 2015

Insiders

Buy orders, 12 months0
Sale orders, 12 months9
Buyers · sellers0 · 7

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders117-10 on the quarter
New · exited15 · 24
Reported value$343.0M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Jupiter Topco LLCnew · filed 14 Aug 20263,654,920$53.3M+3,654,920
BlackRock, Inc.added · filed 7 Aug 20263,244,448$47.3M+140,680+4.5%
FARALLON CAPITAL MANAGEMENT, L.L.C.reduced · filed 14 Aug 20262,418,202$35.3M-453,660−15.8%
Deep Track Capital, LPreduced · filed 14 Aug 20261,444,167$21.1M-512,700−26.2%
ADAR1 Capital Management, LLCadded · filed 14 Aug 20261,344,510$19.6M+1,293,153+2518.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20261,211,769$17.7M+33,720+2.9%
Spruce Street Capital LPadded · filed 13 Aug 20261,088,731$15.9M+156,133+16.7%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 20261,011,494$14.7M+62,590+6.6%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026776,634$11.3M+51,573+7.1%
MILLENNIUM MANAGEMENT LLCreduced · filed 14 Aug 2026643,967$9.4M-238,130−27.0%
31 Mar 2023 – 30 Jun 2026
92109126Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Scott T. Rottinghaus Company insiderChief Medical Officer · last 8 Aug 20260 · 6
Bruce L. A. Carter Company insiderDirector · last 11 Mar 20260 · 4
Kristine Peterson Company insiderDirector · last 11 Mar 20260 · 0
Lesley Russell Company insiderDirector · last 11 Mar 20260 · 0
Mark G. Foletta Company insiderDirector · last 11 Mar 20260 · 0
Terry Vance Company insiderDirector · last 11 Mar 20262 · 1
Yujiro S. Hata Company insiderDirector · last 11 Mar 20260 · 0
Brendan Luu Company insiderChief Business Officer · last 12 Feb 20260 · 3
Jay R. Luly Company insiderPresident and CEO · last 12 Feb 20261 · 19
Matthew Paul Kowalsky Company insiderChief Legal Officer · last 12 Feb 20260 · 0
Tara Lynn Kieffer Company insiderChief Product Strategy Officer · last 12 Feb 20260 · 4
Yat Sun Or Company insiderChief Scientific Officer · last 12 Feb 20260 · 20

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 30 Sep 2025-131%
Free cash flow marginFY 2025 · to 30 Sep 2025-49.2%
Return on capital employedFY 2025 · to 30 Sep 2025-36.8%
Research spendFY 2025 · to 30 Sep 2025163%
Share count trendFY 2025 · to 4 Nov 202535.0%
Cash and equivalentsFY 2025 · to 30 Sep 2025$32.3M
Free cash flowFY 2025 · to 30 Sep 2025−$32.2M

Analyst forecasts

No analyst forecasts yet.